MARKET

KZR

KZR

Kezar Life Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.50
-0.18
-3.17%
Closed 16:01 05/06 EDT
OPEN
5.65
PREV CLOSE
5.68
HIGH
5.65
LOW
5.13
VOLUME
831.16K
TURNOVER
--
52 WEEK HIGH
9.79
52 WEEK LOW
4.240
MARKET CAP
264.44M
P/E (TTM)
-5.6707
1D
5D
1M
3M
1Y
5Y
We're Hopeful That Kezar Life Sciences (NASDAQ:KZR) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 04/19 10:45
Kezar Life Sciences Saturday Morning Announced Preclinical Data With IND Candidate KZR-261 At American Association For Cancer Research Conference
Kezar Life Sciences, Inc. (Nasdaq), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today presented preclinical data on the
Benzinga · 04/12 14:08
Kezar Life Sciences Presents Preclinical Data with IND Candidate KZR-261 at American Association for Cancer Research (AACR) 2021 Virtual Annual Meeting
Kezar Life Sciences, Inc. (Nasdaq), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today presented preclinical data on the company’s novel protein secretion program dur...
Business Wire · 04/10 13:30
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 29)
Benzinga · 03/30 12:06
Kezar Life Sciences reports Q4 results
Kezar Life Sciences (KZR): Non-GAAP EPS of -$0.22.Cash, cash equivalents and marketable securities totaled $140.4M as of December 31, 2020.Press Prelease
Seekingalpha · 03/11 22:42
10-K: KEZAR LIFE SCIENCES, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/11 21:24
Kezar Life Sciences Q4 EPS $(0.22) Up From $(0.50) YoY
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.22) per share. This is a 56 percent increase over losses of $(0.50) per share from the same period last year.
Benzinga · 03/11 21:04
Press Release: Kezar Life Sciences Reports Fourth Quarter and Year End 2020 Financial Results and Provides Business Updates
Dow Jones · 03/11 21:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KZR. Analyze the recent business situations of Kezar Life Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KZR stock price target is 15.00 with a high estimate of 18.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 115
Institutional Holdings: 25.11M
% Owned: 52.22%
Shares Outstanding: 48.08M
TypeInstitutionsShares
Increased
29
2.38M
New
9
191.59K
Decreased
26
833.43K
Sold Out
9
1.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.30%
Key Executives
Chairman/Independent Director
Jean-Pierre Sommadossi
President/Chief Scientific Officer/Director
Christopher Kirk
Chief Executive Officer/Director
John Fowler
Chief Financial Officer/Secretary
Marc Belsky
Senior Vice President
Vassiliki Economides
Other
Noreen Henig
Independent Director
Franklin Berger
Independent Director
Graham Cooper
Independent Director
Jason Dinges
Independent Director
Elizabeth Garner
Independent Director
Michael Kauffman
No Data
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.

Webull offers kinds of Kezar Life Sciences Inc stock information, including NASDAQ:KZR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZR stock methods without spending real money on the virtual paper trading platform.